TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04578405

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intracorporeal anastomosis
Description: Anastomosis performed totally laparoscopically

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal anastomosis
Description: Anastomosis performed through a minilaparotomy
Study: NCT03464721

Intervention type: DEVICE
Intervention: issued with SMART ANGEL device
Description: patients will use the technology at home to record and transmit data for blood pressure and oxygen saturation
Study: NCT02345876

Intervention type: OTHER
Intervention: no intervention

Intervention type: OTHER
Intervention: no intervention
Study: NCT03653988

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PEC I/II blocks by surgeon - intra-operative
Description: PEC I/II blocks by surgeon - intra-operative; PEC I/II block to anesthetize the pectoral, intercostobrachial, third to sixth intercostal and long thoracic nerves. The PEC I/II blocks are pectoralis field blocks where local anesthetic medication is injected under ultrasound guidance between the tissue planes of pectoralis major and minor muscles (PECS I) and in the plane of the serratus anterior muscle at the level of the third rib (PEC II).
Study: NCT01251835

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitaxsentan alone
Description: Days 1-5: Sitaxsentan tablet, 100 mg, q24 h (once a day)
Study: NCT01605747

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Culturelle
Description: one capsule 2x per day per feeding tube
Study: NCT01251835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitaxsentan
Description: Days 6-12: Sitaxsentan tablet, 100 mg, q24h (once a day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Days 6-12: Rifampin capsule, 600 mg, q24h (once a day)
Study: NCT02585921

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video Interventions
Description: Participants will watch 2 5-minute videos and then discuss them as a group.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video Interventions
Description: Participants will watch 2 5-minute videos and then discuss them as a group.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Donation Discussion Education
Description: Participants will learn techniques for introducing and discussing organ donation with parents and guardians.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Donation Discussion Education
Description: Participants will learn techniques for introducing and discussing organ donation with parents and guardians.
Study: NCT04519346

Intervention type: OTHER
Group type: OTHER
Intervention: intradermal injection
Description: Mesotherapy was performed by an experienced and trained physician using disposable 4 mm and 6 mm long 30 Gauge needles (Meso-relle, Biotekne SRL, Italy)to the pericarotid region, glabella, and the area between the eyes and ears, and to the area of the head where pain occurred (such as frontal, parietal, occipital region) for each patient
Study: NCT01157026

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tocotrienol Rich Fraction (TRF)
Description: Tocotrienol Rich Fraction (200mg), daily for five years

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo plus tamoxifen
Description: 20mg tamoxifen daily
Study: NCT02522325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phendimetrazine
Description: Phendimetrazine will be administered in divided doses twice daily.
Study: NCT01485809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Gefitinib 250mg/day, oral daily q every 4 weeks
Study: NCT05192902

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Computer-controlled Local Anaesthesia (CCLA)
Description: The computer-controlled local anesthetic injector Calaject®, (Rønvig Dental MFG, Daugaard, Denmark), which is designed to reduce the pain of performing local anaesthesia. The principle of this device is based on the fact that the less pressure and flow of a local anaesthetic injection, the less painful will be the procedure. Each device has an installed pressure sensor as well as a three-button display that allows choosing the most appropriate program in terms of different speeds and pressure. According to the anaesthesia technique, the manufacture recommends program I for intraligamentary and palatally injections, program II for infiltration and III for alveolar nerve block techniques. Conventional carpules and needles can be used in a pen-shaped part connecting to the main unit. The administration of the anaesthetic can be achieved using a foot control pedal which is adapted to the main unit, the speed of injection is related to acoustic signals.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computer-controlled Local Anaesthesia (CCLA)
Description: The computer-controlled local anesthetic injector Calaject®, (Rønvig Dental MFG, Daugaard, Denmark), which is designed to reduce the pain of performing local anaesthesia. The principle of this device is based on the fact that the less pressure and flow of a local anaesthetic injection, the less painful will be the procedure. Each device has an installed pressure sensor as well as a three-button display that allows choosing the most appropriate program in terms of different speeds and pressure. According to the anaesthesia technique, the manufacture recommends program I for intraligamentary and palatally injections, program II for infiltration and III for alveolar nerve block techniques. Conventional carpules and needles can be used in a pen-shaped part connecting to the main unit. The administration of the anaesthetic can be achieved using a foot control pedal which is adapted to the main unit, the speed of injection is related to acoustic signals.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Conventional Local Anaesthesia
Description: Conventional dental local anaesthetic injections.
Study: NCT01605747

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one placebo 2x per day per feeding tube
Study: NCT04647903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADAIR 10 mg IR tablets
Description: manipulated ADAIR 3x10mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: d-amphetamine sulfate
Description: crushed d-amphetamine sulfate 3x10mg
Study: NCT02522325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cocaine
Description: Intranasal cocaine will be administered during experimental sessions.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cocaine
Description: Intranasal cocaine will be administered during experimental sessions.
Study: NCT04647903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo for oral and intranasal administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo for oral and intranasal administration
Study: NCT02522325

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules will contain only cornstarch.
Study: NCT03472586

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT04657809

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Insulin film
Description: Insulin suspension vials

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Insulin film
Description: Insulin suspension vials

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fast dissolving film
Description: Fast dissolving film
Study: NCT04647903

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: placebo for oral and intranasal administration
Study: NCT04657809

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Fast dissolving film
Description: Fast dissolving film
Study: NCT03328572

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: E-max Endocrown
Description: Endocrown preparation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cerasmart Endocrown
Description: Endocrown preparation
Study: NCT04994860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 5-1058
Description: Oral BIA 5-1058 (Zamicastat) 100 mg tablets
Study: NCT04647903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo for oral and intranasal administration
Study: NCT03127514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMX0035
Description: AMX0035

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo Comparator
Study: NCT05596656

Intervention type: DIAGNOSTIC_TEST
Intervention: skin prick test
Description: Skin prick testing was performed to all diabetic child with history of allergy. The recommended method of prick testing includes the appropriate use of specific allergen extracts, positive and negative controls, interpretation of the tests after 15 - 20 minutes of application, with a positive result defined as a wheal ≥3 mm diameter more than negative control for detection of specific IgE to one or more of common aeroallergens.~The location of each allergen was marked with a pen on the volar aspect of forearm to properly identify test results, at least 2 cm from the wrist and the antecubital fossae. The distance between two skin prick tests should be appropriate to avoid false-positive reactions due to direct contamination of a nearby test. A drop of each test solution should be placed on the skin in identical order for each subject tested and immediately pricked with a single-head metal lancet.

Intervention type: DIAGNOSTIC_TEST
Intervention: skin prick test
Description: Skin prick testing was performed to all diabetic child with history of allergy. The recommended method of prick testing includes the appropriate use of specific allergen extracts, positive and negative controls, interpretation of the tests after 15 - 20 minutes of application, with a positive result defined as a wheal ≥3 mm diameter more than negative control for detection of specific IgE to one or more of common aeroallergens.~The location of each allergen was marked with a pen on the volar aspect of forearm to properly identify test results, at least 2 cm from the wrist and the antecubital fossae. The distance between two skin prick tests should be appropriate to avoid false-positive reactions due to direct contamination of a nearby test. A drop of each test solution should be placed on the skin in identical order for each subject tested and immediately pricked with a single-head metal lancet.
Study: NCT00269425

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: American Heart Association Step 2 diet
Description: Low fat diet with patient education and diet analysis

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Description: Mediterranean style diet with patient education and diet analysis
Study: NCT03505086

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood withdrawal
Description: * Blood withdrawal will be at regular sampling moments, blood can be collected from a central venous catheter or venepuncture procedure.~* Blood withdrawal will be performed for a maximum of 10 times per admission, 10 ml per time.~* Urine sampling will be for a maximum of 5 times per admission.~* Urine can be sampled from a catheter when present, or collected regular.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood withdrawal
Description: * Blood withdrawal will be at regular sampling moments, blood can be collected from a central venous catheter or venepuncture procedure.~* Blood withdrawal will be performed for a maximum of 10 times per admission, 10 ml per time.~* Urine sampling will be for a maximum of 5 times per admission.~* Urine can be sampled from a catheter when present, or collected regular.
Study: NCT04994860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 5-1058
Description: Oral BIA 5-1058 (Zamicastat) 100 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Oral Sildenafil ( Revatio) 20 mg film coated tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: Oral Sildenafil ( Revatio) 20 mg film coated tablets
Study: NCT03505086

Intervention type: OTHER
Intervention: Questionnaire for former bleeding events
Description: Questionnaire to investigate a bleeding tendency before diagnosis.

Intervention type: OTHER
Intervention: Questionnaire for former bleeding events
Description: Questionnaire to investigate a bleeding tendency before diagnosis.
Study: NCT03193281

Intervention type: DRUG
Group type: OTHER
Intervention: Dasatinib
Description: In order to test the study hypothesis patients need to stay on dasatinib (Sprycel) treatment for the first 12 months of the study (Stage 1).~Patients who do not reach MR3.0 at 12 months will remain on dasatinib treatment.

Intervention type: DRUG
Group type: OTHER
Intervention: Imatinib
Description: Patients who reach MR3.0 at 12 months (and the result is confirmed at 13 months) will switch to imatinib (Imatinib-AFT) treatment.
Study: NCT00603369

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: group intervention
Description: 13-session intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: group intervention
Description: 2-session intervention
Study: NCT02237586

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Challenge
Description: live, aseptic, cryopreserved P. falciparum sporozoites

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Challenge
Description: live, aseptic, cryopreserved P. falciparum sporozoites

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Challenge
Description: live, aseptic, cryopreserved P. falciparum sporozoites
Study: NCT01130493

Intervention type: DRUG
Group type: OTHER
Intervention: IPX066
Description: experimental product

Intervention type: DRUG
Group type: OTHER
Intervention: IPX066
Description: experimental product

Intervention type: DRUG
Group type: OTHER
Intervention: CLE
Description: active comparator

Intervention type: DRUG
Group type: OTHER
Intervention: CLE
Description: active comparator
Study: NCT03616457

Intervention type: DEVICE
Intervention: Automated Breast Ultrasound (ABUS)
Description: Participants will undergo imaging with ABUS.
Study: NCT03000062

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: Please see the preceding section
Study: NCT00042601

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pramlintide acetate
Description: Pramlintide injection will be supplied in 5-mL multidose glass vials with rubber stoppers.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo injection will be supplied in 5-mL multidose glass vials with a rubber stopper
Study: NCT03408171

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 19-gauge FNA needle
Description: A 19-gauge FNA needle will be used to obtain liver tissue during an endoscopic-ultrasound guided liver biopsy. Tissue yield and diagnostic accuracy will be assessed and compared to that of the 19-gauge FNB needle.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 19-gauge FNB needle
Description: A 19-gauge FNB needle will be used to obtain liver tissue during an endoscopic-ultrasound guided liver biopsy. Tissue yield and diagnostic accuracy will be assessed and compared to that of the 19-gauge FNA needle.
Study: NCT03064724

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive Mobile Doctor (iMD)
Description: iMD delivers tailored interactive video education via a mobile tablet to smoking patients right before their clinic visit with a provider. iMD delivers the 5 A's (ask, advise, assess, assist, and arrange) and generates a bilingual tailored printout, which aims to increase patient-provider discussion on tobacco use and to promote smoking cessation. This version of iMD delivers the intervention in Korean or Vietnamese languages as preferred by the patient.
Study: NCT00307086

Intervention type: DRUG
Group type: OTHER
Intervention: Bortezomib
Description: the maximum tolerated dose (MTD) of bortezomib in combination with high-dose melphalan as a conditioning regimen for autologous stem cell transplant

Intervention type: DRUG
Group type: OTHER
Intervention: Melphalan
Description: Day -4 melphalan 100 mg/m2 intravenously over 30 minutes, Day -3 melphalan 100 mg/m2 intravenously over 30 minutes

Intervention type: PROCEDURE
Group type: OTHER
Intervention: PBSCT
Description: PBSCT #1 Day 0 PBSCT #2 Day 0 (approx 90 days =/- 15 days after PBSCT #1)
Study: NCT03618017

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CCC website
Description: ConnectedCancerCare (CCC) is a web-based guide to support survivorship care for women who have been treated for early-stage (stages 0-II) breast cancer. It encourages patients to utilize team-based care by oncologists and primary care physicians and provides them with the information on cancer surveillance, screenings and preventive healthcare during survivorship.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Static care plan
Description: The control is a static survivorship care plan template in PDF format that includes information similar to what an oncologist currently provides as standard of care.
Study: NCT05190939

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: water as bladder distending media
Description: water will be used for bladder dissension during cystoscopy

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: water as bladder distending media
Description: water will be used for bladder dissension during cystoscopy

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: intravenous dye
Description: intravenous dye using methylene blue or fluorescein will be used for visual aid of ureteral jets during cystoscopy

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: intravenous dye
Description: intravenous dye using methylene blue or fluorescein will be used for visual aid of ureteral jets during cystoscopy

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: No intervention
Description: Saline only, no dye
Study: NCT03032848

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conjugated Estrogen
Description: use of 1 gram per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conjugated Estrogen
Description: use of 1 gram per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Conjugated Estrogen
Description: use of 1 gram per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Promestriene
Description: use of 1 gram per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Promestriene
Description: use of 1 gram per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Promestriene
Description: use of 1 gram per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estriol
Description: use of 1 gram per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estriol
Description: use of 1 gram per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Estriol
Description: use of 1 gram per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal Moisturizer - Cream
Description: use of 1 gram per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal Moisturizer - Cream
Description: use of 1 gram per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal Moisturizer - Cream
Description: use of 1 gram per day
Study: NCT03732430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI308
Description: A humanized anti-PD-1 monoclonal antibody
Study: NCT05565430

Intervention type: OTHER
Intervention: Acute Hyperventilation
Description: Laryngoscopy to assess vocal cord function during acute hyperventilation in normal subjects and asthmatics.

Intervention type: OTHER
Intervention: Acute Hyperventilation
Description: Laryngoscopy to assess vocal cord function during acute hyperventilation in normal subjects and asthmatics.

Intervention type: OTHER
Intervention: Acute Hyperventilation
Description: Laryngoscopy to assess vocal cord function during acute hyperventilation in normal subjects and asthmatics.
Study: NCT03472586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Embolization Therapy
Description: Undergo immunoembolization
Study: NCT03070899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OBE2109
Description: OBE2109 100mg tablets for oral administration once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OBE2109
Description: OBE2109 100mg tablets for oral administration once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OBE2109
Description: OBE2109 100mg tablets for oral administration once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OBE2109
Description: OBE2109 100mg tablets for oral administration once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: OBE2109
Description: OBE2109 100mg tablets for oral administration once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match OBE2109
Description: Placebo to match OBE2109 100mg tablets for oral administration once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match OBE2109
Description: Placebo to match OBE2109 100mg tablets for oral administration once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match OBE2109
Description: Placebo to match OBE2109 100mg tablets for oral administration once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match Add-back
Description: Placebo to match Add-back (E2 1 mg / NETA 0.5 mg) for oral administration once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match Add-back
Description: Placebo to match Add-back (E2 1 mg / NETA 0.5 mg) for oral administration once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match Add-back
Description: Placebo to match Add-back (E2 1 mg / NETA 0.5 mg) for oral administration once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Add-back
Description: Add-back (E2 1 mg / NETA 0.5 mg) for oral administration once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Add-back
Description: Add-back (E2 1 mg / NETA 0.5 mg) for oral administration once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Add-back
Description: Add-back (E2 1 mg / NETA 0.5 mg) for oral administration once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Add-back
Description: Add-back (E2 1 mg / NETA 0.5 mg) for oral administration once daily
Study: NCT00721188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venofer
Description: Single dose of 7mg intravenous (IV) of iron per kg of body weight for a maximum of 200mg iron IV.
Study: NCT01266590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2216684
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Administered orally